Corbus Pharmaceuticals Holdings Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
On June 14, 2024, Yong Ben M.D., a member of theboard of directors, adopted a Rule 10b5-1 plan providing for the sale of up to 10,607 shares of the Company’s common stock. Pursuant to this plan, Dr. Ben may sell shares of common stock beginning on September 12, 2024, subject to the terms of the agreement, and the plan terminates on September 11, 2025. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
No other directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the second quarter of 2024.
On August 1, 2024, the loan in connection with the Loan and Security Agreement with K2HV matured. On August 1, 2024, the Company made a $11.8 million payment to K2HV which paid off the loan in full.
-29-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.